Happy to announce publication of our new paper: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy | Nature Biomedical Engineering Congratulations, Angel and Team!!!

A new CHOP study finds that combining a specialized diet with an approved medication interrupts the growth of high-risk neuroblastoma by reprogramming tumor behavior. Learn more at: https://t.co/qMzAEU9tPg. @Nature

Durable CAR T persistence is among the great unsolved challenges within our field. But what do we actually mean when we say a CAR T cell is "persistent"? @JGrenierMDPhD, @EvanWeberPhD and I attempt to answer this question in our new review @trendscancer. 1/

https://t.co/9M132CIhWe

In an exciting collaboration with the #ImmuneHealth lab at Penn @benfens investigated the developing immune system of preterm infants. Even pre-term infants make surprisingly robust CD8 T cell responses to diverse infections.

So grateful for this generous support for our work from @chadtough and @laceemupforlibby!

"Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death" #HLH travels under many names (#MAS, #CRS, ...), all united by T-cell hyperactivation. https://t.co/F1aJAumXdE

Next-generation IL18-armored CAR T cell therapy shows promise for patients whose lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. @carlhjune @NEJM

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" @PennMedicine @nejm #immunotherapy https://t.co/sFTP4YWpWT

Introducing, the Canada Strong Pass.

Great turnout in Philly for #StandUpForScience2025 #NIH

@EvanWeberPhD @kpmueller1 @CancerResearch Congratulations @kpmueller1 and @EvanWeberPhD on this well-deserved fellowship! Great talent and amazing mentorship 🤩🎉

Congratulations to Eugene Khandros (@ChildrensPhila/ @PennMedicine) on being named a 2025 @the_asci Young Physician-Scientist Awardee! https://t.co/Pc5RkbDZbt Learn more about Dr. Khandros & his work here➡️ https://t.co/2eunBs593Z @CHOP_Research

Couldn’t be more thrilled to announce the start of my independent research group ‘Precision Immunotherapy’ starting next week in the Department of Hematology and Oncology at the University Hospital of the @LMU_Muenchen 🚀🚀 #newpi #prouddrylab #clinicianscientist #bzkf #lmu

“The impact of the collective executive orders and directives appears devastating.”

Thrilled to share our new paper in @NatureMedicine! We analyzed 783 patients (2,200+ patient-years) receiving lentiviral or gammaretroviral T cell therapies and found no evidence of high-level insertional mutagenesis.

Excited to share our latest work in @NatureCancer to get a better understanding why relapsed T-ALL is so deadly and potential target strategies, led by Jason Xu and @changya1 with members of David Teachey, @junjyang, @CMullighan and many great colleagues. https://t.co/SaG7Q74FMS.

@CancerResearch @EvanWeberPhD @ChildrensPhila I am deeply grateful for my colleagues and mentors who supported me through many iterations of this proposal. Huge thanks in particular to Suzi McClory, Alice Wang, @CarolineDiorio, @GruppSteve, and @KaiTanLab1, all incredible collaborators who have taught me so much. 2/

Excited to share our first story from the lab (and some good news!) led by the impressive Morgan Drucker @cincychildrens and Darren Lee @cincymedicine looking at clonal evolution in NPM1-mut AML at single cell resolution! 🧵/1

Congrats to @ChildrensPhila's Dr. Evan Weber, recipient of the @NIHDirector's New Innovator Award! Dr. Weber will pursue a novel approach to reprogram T cells with enhanced tumor killing function, paving the way for more efficacious #cancer therapeutics. @CHOPCancerCntr